Enlarge
Joe Wojcik
Cognition Therapeutics Inc. CEO Hank Safferstein and Chief Science Officer Susan Catalano, in the company's South Side labs.
Cognition Therapeutics has secured $3 million of a $3.5 million raise, said company CEO Hank Safferstein[1] . The money will allow the company to keep advancing its small molecule program as it works to secure a larger Series B round.
South Side-based cognition is developing a small molecule[2] and new target to treat Alzheimer’s disease.
This latest raise includes existing investors and a couple new individuals, Safferstein said, but declined to get into details.
Malia Spencer covers energy and technology. Contact her at mspencer@bizjournals.com[3] or 412-208-3829. You can also follow her on Twitter[4] .
References
- ^ Hank Safferstein (www.bizjournals.com)
- ^ developing a small molecule (www.bizjournals.com)
- ^ mspencer@bizjournals.com (www.bizjournals.com)
- ^ Twitter (twitter.com)
0 comments:
Post a Comment